HK1125853A1 - Polypeptides homologous to vegf and bmp1 - Google Patents

Polypeptides homologous to vegf and bmp1

Info

Publication number
HK1125853A1
HK1125853A1 HK09104617.6A HK09104617A HK1125853A1 HK 1125853 A1 HK1125853 A1 HK 1125853A1 HK 09104617 A HK09104617 A HK 09104617A HK 1125853 A1 HK1125853 A1 HK 1125853A1
Authority
HK
Hong Kong
Prior art keywords
vegf
bmp1
growth factor
polypeptides homologous
vascular endothelial
Prior art date
Application number
HK09104617.6A
Other languages
English (en)
Inventor
Napoleone Ferrara
Sophia S Kuo
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/040,220 external-priority patent/US6391311B1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HK1125853A1 publication Critical patent/HK1125853A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK09104617.6A 1998-03-17 2009-05-20 Polypeptides homologous to vegf and bmp1 HK1125853A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/040,220 US6391311B1 (en) 1998-03-17 1998-03-17 Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
US18421698A 1998-11-02 1998-11-02

Publications (1)

Publication Number Publication Date
HK1125853A1 true HK1125853A1 (en) 2009-08-21

Family

ID=26716852

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09104617.6A HK1125853A1 (en) 1998-03-17 2009-05-20 Polypeptides homologous to vegf and bmp1

Country Status (14)

Country Link
US (11) US6455283B1 (fr)
EP (2) EP1064382B1 (fr)
JP (3) JP4532733B2 (fr)
AT (1) ATE405651T1 (fr)
AU (1) AU758353B2 (fr)
CA (1) CA2322792C (fr)
CY (2) CY1108500T1 (fr)
DE (1) DE69939374D1 (fr)
DK (2) DK2016951T3 (fr)
ES (2) ES2313778T3 (fr)
HK (1) HK1125853A1 (fr)
IL (5) IL138488A0 (fr)
PT (1) PT2016951E (fr)
WO (1) WO1999047677A2 (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053760A2 (fr) * 1999-03-12 2000-09-14 Genentech, Inc. Technique permettant de prevenir la mort des neurones retiniens et traitement des maladies oculaires
CA2319112C (fr) 1998-02-13 2003-10-28 Genetrace Systems, Inc. Utilisation de ribozymes afin d'identifier la fonction de genes
CA2349562A1 (fr) * 1998-03-06 1999-09-10 Crosscart, Inc. Xenogreffes de tissus mous
EP1064382B1 (fr) * 1998-03-17 2008-08-20 Genentech, Inc. Polypeptides homologues aux vegf et bmp1
EP0984063A3 (fr) * 1998-08-31 2000-08-16 Eli Lilly And Company Gene et proteine apparentee au vegf
DK1137773T3 (da) * 1998-12-07 2008-12-08 Zymogenetics Inc Væsktfaktorhomolog ZVEGF3
US6432673B1 (en) * 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
US6663870B2 (en) * 1998-12-07 2003-12-16 Zymogenetics, Inc. Methods for promoting growth of bone using zvegf3
NZ512892A (en) * 1998-12-22 2003-08-29 Janssen Pharmaceutica Nv VEGF-X and the CUB domain of VEGF-X, which prevents angiogenesis and is used to treat inappropriate vascularisation and angiogenesis
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
WO2000039284A1 (fr) * 1998-12-30 2000-07-06 Millennium Pharmaceuticals, Inc. Proteines secretees et acides nucleiques codant ces proteines
AU3514400A (en) * 1999-03-08 2000-09-28 Genentech Inc. Compositions and methods for the treatment of immune related diseases
WO2000059940A2 (fr) * 1999-04-06 2000-10-12 Eli Lilly And Company Gene et proteine lies au facteur de croissance d'origine plaquettaire
US6630142B2 (en) * 1999-05-03 2003-10-07 Zymogenetics, Inc. Method of treating fibroproliferative disorders
EP1222279A2 (fr) * 1999-10-07 2002-07-17 Curagen Corporation Polypeptides agissant comme facteur de croissance et acides nucleiques codant pour ces derniers
US6893637B1 (en) * 1999-10-21 2005-05-17 Zymogenetics, Inc. Method of treating fibrosis
AU8031700A (en) * 1999-10-21 2001-04-30 Zymogenetics Inc. Method of treating fibrosis
AU1430601A (en) * 1999-11-02 2001-05-14 Eli Lilly And Company Methods of using lp8, a pdgf-related protein, to treat musculoskeletal disorders
AU2925401A (en) * 2000-01-19 2001-07-31 Parkash S Gill Methods and compositions for antisense vegf oligonucleotides
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
WO2001072132A1 (fr) * 2000-03-28 2001-10-04 Ludwig Institute For Cancer Research Animaux transgeniques non humains exprimant un facteur de croissance c derive de plaquettes (pdgf-c) et utilisations
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US20070111935A1 (en) * 2000-04-06 2007-05-17 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US20040023863A1 (en) * 2000-04-06 2004-02-05 Franco Wayne P. Methods of use growth factors for treating heart disease
US7166280B2 (en) * 2000-04-06 2007-01-23 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
US20050277576A1 (en) * 2000-04-06 2005-12-15 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
WO2001076620A2 (fr) * 2000-04-12 2001-10-18 Vlaams Interuniversitair Instituut Voor Biotecnologie Vzw Utilisation de vegf et d'homologues pour traiter des troubles du neurone
AU6595301A (en) * 2000-05-12 2001-11-20 Vlaams Interuniv Inst Biotech Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
EP1311277A4 (fr) * 2000-07-18 2004-08-25 Joslin Diabetes Center Inc Procede de modulation de fibrose
US20020091082A1 (en) * 2000-09-13 2002-07-11 Aiello Lloyd P. Methods of modulating symptoms of hypertension
US20040086507A1 (en) * 2000-10-19 2004-05-06 Kenya Shitara Antibody inhibiting vplf activity
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7026462B2 (en) 2000-12-07 2006-04-11 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
JP2004527506A (ja) * 2001-03-09 2004-09-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 平滑筋細胞増殖のモジュレーション
US6913762B2 (en) * 2001-04-25 2005-07-05 Mayo Foundation For Medical Education And Research Stent having non-woven framework containing cells
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
ATE526041T1 (de) * 2001-12-11 2011-10-15 Fibrogen Inc Verfahren zur hemmung okularer vorgänge
WO2003092665A2 (fr) * 2002-05-02 2003-11-13 Massachusetts Eye And Ear Infirmary Systemes oculaires de distribution de medicament et utilisation associee
JP2005524710A (ja) * 2002-05-06 2005-08-18 ジェネンテック・インコーポレーテッド 骨欠陥の治療へのｖｅｇｆの用途
AU2003245935A1 (en) * 2002-06-13 2003-12-31 Novuspharma S.P.A. Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells
US20040052161A1 (en) * 2002-09-17 2004-03-18 Steven Liao Mechanical clock having wireless manipulation and adjustment function
JP4741249B2 (ja) 2002-11-16 2011-08-03 シーメンス・ヘルスケア・ダイアグノスティックス・プロダクツ・ゲーエムベーハー 心血管疾患における生化学的マーカーの組合せとしてのｓＣＤ４０Ｌ，ＰＡＰＰ−Ａおよび胎盤増殖因子（ＰｌＧＦ）
US20090155266A1 (en) * 2004-01-16 2009-06-18 Yale University Methods and Compositions Relating to Vascular Endothelial Growth Factor and TH2 Mediated Inflammatory Diseases
WO2005087812A1 (fr) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Substances d'anticorps polyvalentes et procedes pour la famille vegf/pdgf des facteurs de croissance
US20060024302A1 (en) * 2004-03-05 2006-02-02 Ludwig Institute For Cancer Research Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
US8415315B2 (en) 2004-05-06 2013-04-09 University Of Central Florida Research Foundation, Inc. Methods and compositions for inhibiting the proliferation of cancer cells
PT1755647E (pt) 2004-05-27 2010-09-29 Vzw Vib Tratamento da esclerose lateral amiotrófica
US20060045902A1 (en) * 2004-09-01 2006-03-02 Serbousek Jon C Polymeric wrap for in vivo delivery of osteoinductive formulations
DE102004051847B4 (de) * 2004-10-25 2008-09-18 Dade Behring Marburg Gmbh Verhältnis von PIGF und Flt-1 als prognostischer Parameter bei kardio-vaskulären Erkrankungen
PT1869085E (pt) * 2005-03-24 2012-06-01 Vlaams Interuniv Inst Biotech Vzw Novo anticorpo anti-plgf
ATE502956T1 (de) * 2005-08-15 2011-04-15 Vegenics Pty Ltd Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften
US8114399B2 (en) 2006-05-17 2012-02-14 Ludwig Institute For Cancer Research Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases
ES2354922B1 (es) 2009-09-02 2012-02-07 Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer.
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
EA018848B1 (ru) * 2010-10-20 2013-11-29 Вадим Юльевич ШАНИН Иммунологически активное вещество, способ его получения, биозонд на его основе и способ диагностики состояния здоровья с применением биозонда, фармацевтическая композиция и способ лечения с использованием фармацевтической композиции
EP2785739B1 (fr) 2011-12-01 2017-03-15 ThromboGenics N.V. Amélioration du résultat de la trabéculectomie
CA2871528A1 (fr) 2012-04-24 2013-10-31 Thrombogenics N.V. Anticorps anti-pdgf-c
AU2013263502B2 (en) * 2012-05-18 2018-02-08 Otago Innovation Limited Combination treatments and compositions for wound healing
EP2968391A1 (fr) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Molécules polynucléotidiques à longue durée de vie
CN105713095B (zh) * 2016-03-14 2021-05-07 南京安吉生物科技有限公司 一种多功能融合多肽及其制备方法和应用
KR101943081B1 (ko) * 2017-08-31 2019-01-29 (주)케어젠 주름 개선 활성을 나타내는 펩타이드 및 이의 용도

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2035733A (en) * 1935-06-10 1936-03-31 Marathon Electric Mfg Fan motor mounting
US2813673A (en) * 1953-07-09 1957-11-19 Gilbert Co A C Tiltable oscillating fan
US2765977A (en) * 1954-10-13 1956-10-09 Morrison Hackley Electric ventilating fans
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
ATE12348T1 (de) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4568243A (en) * 1981-10-08 1986-02-04 Barry Wright Corporation Vibration isolating seal for mounting fans and blowers
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
EP0088046B1 (fr) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipides en phase aqueuse
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (fr) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipides et composés tensio-actifs en phase aqueuse
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
ATE159858T1 (de) 1983-09-26 1997-11-15 Ehrenfeld Udo Mittel und erzeugnis für die diagnose und therapie von tumoren sowie zur behandlung von schwächen der zelligen und humoralen immunabwehr
EP0143949B1 (fr) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Composition pharmaceutique contenant de l'urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4703152A (en) * 1985-12-11 1987-10-27 Holmes Products Corp. Tiltable and adjustably oscillatable portable electric heater/fan
WO1987005330A1 (fr) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Procede pour ameliorer la stabilite des glycoproteines
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5631142A (en) 1986-07-01 1997-05-20 Genetics Institute, Inc. Compositions comprising bone morphogenetic protein-2 (BMP-2)
US5106748A (en) 1986-07-01 1992-04-21 Genetics Institute, Inc. Dna sequences encoding 5 proteins
IL83003A (en) * 1986-07-01 1995-07-31 Genetics Inst Factors that soak bone formation
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US4877864A (en) 1987-03-26 1989-10-31 Genetics Institute, Inc. Osteoinductive factors
US5543394A (en) 1986-07-01 1996-08-06 Genetics Institute, Inc. Bone morphogenetic protein 5(BMP-5) compositions
US4850804A (en) * 1986-07-07 1989-07-25 Tatung Company Of America, Inc. Portable electric fan having a universally adjustable mounting
ES2032831T5 (es) 1986-08-19 2001-02-16 Genentech Inc Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
EP0266032A1 (fr) 1986-08-29 1988-05-04 Beecham Group Plc Enzyme fibrinolytique modifiée
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
JP2755395B2 (ja) 1987-09-23 1998-05-20 ブリストル―マイアーズ スクイブ コムパニー Ｈｉｖ感染細胞に殺作用する抗体異種結合体
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
WO1991000360A1 (fr) 1989-06-29 1991-01-10 Medarex, Inc. Reactifs bispecifiques pour le traitement du sida
CA2020729A1 (fr) 1989-07-19 1991-01-20 Michael C. Kiefer Proteine morphogenetique des os
EP0416578B1 (fr) 1989-09-06 1996-07-31 Takeda Chemical Industries, Ltd. Protéine, ADN et leur utilisation
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5126323A (en) 1989-11-16 1992-06-30 Genetics Institute, Inc. Homogeneous purified k-fgf and compositions containing the same
USD325435S (en) * 1990-09-24 1992-04-14 Vornado Air Circulation Systems, Inc. Fan support base
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
EP0586505A1 (fr) 1991-05-14 1994-03-16 Repligen Corporation Anticorps d'heteroconjugues pour le traitement des infections a l'hiv
US5382569A (en) 1991-05-16 1995-01-17 Warner-Lambert Company Endotherlin antagonists
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
AU652472B2 (en) 1991-06-25 1994-08-25 Genetics Institute, Llc BMP-9 compositions
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
US5296769A (en) * 1992-01-24 1994-03-22 Electrolux Corporation Air guide assembly for an electric motor and methods of making
WO1993024640A2 (fr) 1992-06-04 1993-12-09 The Regents Of The University Of California PROCEDES ET COMPOSITIONS UTILISES DANS UNE THERAPIE GENIQUE $i(IN VIVO)
GB9214857D0 (en) 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
ES2360641T3 (es) * 1992-10-28 2011-06-07 Genentech, Inc. Uso de antagonistas del factor de crecimiento endotelial vascular.
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5310313A (en) * 1992-11-23 1994-05-10 Chen C H Swinging type of electric fan
PT616812E (pt) 1993-03-24 2000-04-28 Berlex Biosciences Combinacao de compostos anti-hormonais e moleculas de ligacao no tratamento do cancro
WO1994023638A2 (fr) 1993-04-05 1994-10-27 University Of Utah Research Foundation Diagnostic et traitement du retrecissement aortique supravalvulaire ou syndrome de williams et beurene
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
US5641756A (en) * 1993-07-27 1997-06-24 Hybridon, Inc. Modified VEGF oligonucleotides
KR100329409B1 (ko) 1993-08-26 2002-03-20 브루스 엠. 에이센, 토마스 제이 데스로저 인간 골 형태발생 단백질을 사용한 신경 재생법
US5773223A (en) 1993-09-02 1998-06-30 Chiron Corporation Endothelin B1, (ETB1) receptor polypeptide and its encoding nucleic acid methods, and uses thereof
US5399677A (en) 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
CA2176942C (fr) 1993-12-07 2011-11-01 Anthony J. Celeste Bmp-12, bmp-13 et compositions de celles-ci pour l'induction de tendons
EP0755446B1 (fr) 1994-04-25 2006-09-13 Genentech, Inc. Cardiotrophine et ses utilisations
US5454419A (en) 1994-09-19 1995-10-03 Polybore, Inc. Method for lining a casing
US5681746A (en) 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5518370A (en) * 1995-04-03 1996-05-21 Duracraft Corporation Portable electric fan with swivel mount
SG68529A1 (en) 1995-05-25 1999-11-16 Univ Singapore The use of des-aspartate-angiotensin i (agr-val-tyr-ile-his-pro-phe-his-leu) as an anti-cardiac hypertrophic agent
SK120098A3 (en) * 1996-02-28 1999-03-12 Bayer Ag Parapoxviruses containing foreign dna, their production and their use in vaccines
WO1997033551A2 (fr) 1996-03-15 1997-09-18 Millennium Pharmaceuticals Compositions et procedes de diagnostic, de prevention et de traitement de la croissance et de la proliferation de cellules neoplasiques
EP0938556B1 (fr) * 1996-07-12 2005-03-09 Genentech, Inc. Gamma-hereguline
WO1998006724A1 (fr) 1996-08-09 1998-02-19 Yamanouchi Pharmaceutical Co., Ltd. Agonistes du recepteur du glutamate metabotropique
WO1998007832A1 (fr) * 1996-08-23 1998-02-26 Ludwig Institute For Cancer Research Facteur d recombinant de croissance des cellules endotheliales vasculaires (vegf-d)
NZ500077A (en) 1997-04-07 2001-10-26 Genentech Inc Humanized antibodies to vascular endothelial growth factor (VEGF) and methods for their preparation.
USD398983S (en) * 1997-08-08 1998-09-29 Vornado Air Circulation Systems, Inc. Fan
US6391311B1 (en) * 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
WO1999037671A1 (fr) 1998-01-27 1999-07-29 Eli Lilly And Company Gene et proteine associes au facteur de croissance des cellules endotheliales vasculaires
NZ507435A (en) 1998-03-10 2003-12-19 Genentech Inc Novel polypeptides and nucleic acids with homology to cornichon
EP1064382B1 (fr) 1998-03-17 2008-08-20 Genentech, Inc. Polypeptides homologues aux vegf et bmp1
WO2000004183A1 (fr) 1998-07-15 2000-01-27 Human Genome Sciences, Inc. Proteine morphogenetique osseuse
JP2002525086A (ja) 1998-09-30 2002-08-13 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ 血小板由来増殖因子ｃ、それをコードするｄｎａ、及びその利用法
WO2000024774A2 (fr) 1998-10-28 2000-05-04 Incyte Pharmaceuticals, Inc. Molecules apparentees au facteur de croissance
US20030027998A1 (en) * 1998-10-30 2003-02-06 Holtzman Douglas A. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
AU771751C (en) 1998-12-01 2006-04-06 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US6432673B1 (en) * 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
DK1137773T3 (da) 1998-12-07 2008-12-08 Zymogenetics Inc Væsktfaktorhomolog ZVEGF3
NZ512892A (en) 1998-12-22 2003-08-29 Janssen Pharmaceutica Nv VEGF-X and the CUB domain of VEGF-X, which prevents angiogenesis and is used to treat inappropriate vascularisation and angiogenesis
WO2000039284A1 (fr) 1998-12-30 2000-07-06 Millennium Pharmaceuticals, Inc. Proteines secretees et acides nucleiques codant ces proteines
US6155782A (en) * 1999-02-01 2000-12-05 Hsu; Chin-Tien Portable fan
AU3514400A (en) 1999-03-08 2000-09-28 Genentech Inc. Compositions and methods for the treatment of immune related diseases
WO2000059940A2 (fr) 1999-04-06 2000-10-12 Eli Lilly And Company Gene et proteine lies au facteur de croissance d'origine plaquettaire
AU4714500A (en) 1999-05-03 2000-11-17 Zymogenetics Inc. Growth factor homolog zvegf4
US6321034B2 (en) * 1999-12-06 2001-11-20 The Holmes Group, Inc. Pivotable heater
AU2003215163A1 (en) * 2002-02-12 2003-09-04 Vanderbilt University Inhibition of vegf receptor signaling reverses tumor resistance to radiotherapy
BR0201397B1 (pt) * 2002-04-19 2011-10-18 arranjo de montagem para um ventilador de refrigerador.
US6830433B2 (en) * 2002-08-05 2004-12-14 Kaz, Inc. Tower fan
US7059826B2 (en) * 2003-07-25 2006-06-13 Lasko Holdings, Inc. Multi-directional air circulating fan
US20050128698A1 (en) * 2003-12-10 2005-06-16 Huang Cheng Y. Cooling fan
WO2005087812A1 (fr) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Substances d'anticorps polyvalentes et procedes pour la famille vegf/pdgf des facteurs de croissance
US7088913B1 (en) * 2004-06-28 2006-08-08 Jcs/Thg, Llc Baseboard/upright heater assembly
CN2835669Y (zh) * 2005-09-16 2006-11-08 霍树添 立柱式电风扇的送风机构

Also Published As

Publication number Publication date
EP2016951A1 (fr) 2009-01-21
IL189572A0 (en) 2009-02-11
JP5931801B2 (ja) 2016-06-08
EP1064382A2 (fr) 2001-01-03
JP5473441B2 (ja) 2014-04-16
DK2016951T3 (da) 2012-09-24
US20070031929A1 (en) 2007-02-08
DK1064382T3 (da) 2008-12-08
US20090012003A1 (en) 2009-01-08
PT2016951E (pt) 2012-09-27
WO1999047677A3 (fr) 1999-11-11
AU758353B2 (en) 2003-03-20
IL138488A0 (en) 2001-10-31
ATE405651T1 (de) 2008-09-15
ES2313778T3 (es) 2009-03-01
US20040235740A1 (en) 2004-11-25
US20080095773A1 (en) 2008-04-24
CY1108500T1 (el) 2014-04-09
JP4532733B2 (ja) 2010-08-25
US6620784B1 (en) 2003-09-16
IL189571A0 (en) 2009-02-11
US6455283B1 (en) 2002-09-24
US20040219640A1 (en) 2004-11-04
DE69939374D1 (de) 2008-10-02
JP2004515201A (ja) 2004-05-27
US7575879B2 (en) 2009-08-18
CA2322792C (fr) 2010-09-14
US20110319327A1 (en) 2011-12-29
US7371377B2 (en) 2008-05-13
EP2016951B1 (fr) 2012-06-27
AU758353C (en) 1999-10-11
US20030113870A1 (en) 2003-06-19
ES2389387T3 (es) 2012-10-25
WO1999047677A2 (fr) 1999-09-23
JP2013224300A (ja) 2013-10-31
IL189573A0 (en) 2009-02-11
CY1113126T1 (el) 2016-04-13
IL138488A (en) 2008-06-05
IL189572A (en) 2013-01-31
JP2010001292A (ja) 2010-01-07
AU3075099A (en) 1999-10-11
US20090264370A9 (en) 2009-10-22
EP1064382B1 (fr) 2008-08-20
US20100331251A1 (en) 2010-12-30
US7494977B2 (en) 2009-02-24
CA2322792A1 (fr) 1999-09-23
US20080299119A1 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
HK1125853A1 (en) Polypeptides homologous to vegf and bmp1
EP0484401A4 (en) Production of vascular endothelial cell growth factor
AU582225B2 (en) Xenogeneic collagen/mineral preparations in bone repair
AU7783587A (en) Novel osteoinductive compositions
AU5649586A (en) Partially purified bone-inducing factor
DE60007079D1 (de) Methoden und zusammensetzungen zur heilung und reparatur von gelenkknorpeln
CA2104678A1 (fr) Morphogenese induite par des proteines
Han et al. Collagen‐targeted BMP3 fusion proteins arrayed on collagen matrices or porous ceramics impregnated with Type I collagen enhance osteogenesis in a rat cranial defect model
NZ335109A (en) Stable analogs of keratinocyte growth factor (KRF) useful for preventing alopecia, treating gastro-duodenal ulcers, bowel disease, liver function or general induction epithelial cell proliferation
ATE117558T1 (de) Verbesserte resorbierbare knochenwachse.
ATE404668T1 (de) Wachstumsfaktor-homologe zvegf-3
ATE339878T1 (de) Myc-bindende zinkfinger-proteine, ihre herstellung und ihre verwendung
ATE123056T1 (de) Ancrod-proteine, ihre herstellung und verwendung.
ES2186501A1 (es) Factor de crecimiento fibroblastico basico con un dominio de union especifico a colegeno.
DE59106997D1 (de) Ancrod ähnliche proteine, ihre herstellung und verwendung.
WO1999062931A3 (fr) Proteine de signalisation de densite cellulaire permettant de traiter des lesions et des defauts du tissu conjonctif
RU2000113937A (ru) НОВЫЙ ФАКТОР РОСТА/ДИФФЕРЕНЦИАЦИИ TGF-β-СЕМЕЙСТВА И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20190309